Phaseline

Targets › HCN4

HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 4; Cardiovascular, Infectious disease; next expected readout Dec 2026.

Hyperpolarization-activated ion channel that are permeable to Na(+) and K(+) ions with very slow activation and inactivation. Exhibits higher selectivity for K(+) over Na(+) ions. (UniProt, Q9Y3Q4)

Open in Phaseline: the race on HCN4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Second Affiliated Hospital of Guangzhou Medical UniversityIvabradine
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
HCN4Phase 4SepsisDec 2026
National Institute of Cardiovascular Diseases, PakistanIvabradine
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
HCN4Phase 3Cardiogenic Shock Post Myocardial InfarctionMay 2027
Jagiellonian UniversityIvabradine
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
HCN4Phase 3Myocardial Injury After Noncardiac Surgery (MINS)–

Conditions

Sepsis (1) Cardiogenic Shock Post Myocardial Infarction (1) Myocardial Injury After Noncardiac Surgery (MINS) (1)

Modalities

small molecule (3)

Companies

Second Affiliated Hospital of Guangzhou Medical University (1) National Institute of Cardiovascular Diseases, Pakistan (1) Jagiellonian University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.